drug development

2 articles tagged “drug development”

NASH Fibrosis & Peptide Therapy

NASH Fibrosis Peptide Therapy Reversal

In March 2024, the FDA approved resmetirom for NASH, marking the first regulatory victory after two decades of failed Phase 3 trials—yet NASH fibrosis progression and peptide therapy's potential role in reversing scarring remain largely unexplored in clinical settings.

AdminUpdated Aug 119 min

Regulatory & Approval Status

Why BPC-157 Isn't FDA Approved Yet

After 30 years and 150 peer-reviewed publications, BPC-157 remains without FDA approval—a puzzle that reveals how regulatory pathways, funding constraints, and the absence of large-scale human trials can stall a compound indefinitely.

AdminUpdated Jul 2810 min